Navigation Links
Matrixx Initiatives, Inc. Sets Time for Discussion of Recent FDA Action
Date:6/17/2009

SCOTTSDALE, Ariz., June 17 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company announced today that they will hold a conference call to discuss recent actions on Thursday, June 18, 2009 at 11:00 AM ET.

To access the teleconference, please call (877) 719-9795 (domestic) or (719) 325-4805 (international). To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on Events & Presentations.

A replay of the call will be available at (888) 203-1112 (domestic) or (719) 457-0820 (international), replay code 7864652 for 3 days following the call, and the web cast will be archived on the company's website, http://www.matrixxinc.com, for 30 days.

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam(R) products in the cough and cold category. The Company manufactures and markets a full line of Zicam brand pharmaceuticals, including Zicam Cold Remedy Swabs(TM); Zicam Cold Remedy Chewables(TM); Zicam Cold Remedy Oral Mist(TM); Zicam Cold Remedy RapidMelts(TM); Zicam Allergy Relief; Zicam Extreme Congestion Relief; Zicam Sinus Relief; as well as Zicam Cough products and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq:

SOURCE Matrixx Initiatives, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
3. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
4. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
5. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
6. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
7. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
8. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2008 Financial Results
9. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
10. Matrixx Initiatives Selects GolinHarris as Agency of Record for Zicam Brand
11. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... 2015 Thousands of transvaginal mesh ... C.R. Bard, Inc. continue to move forward in ... Southern District of West Virginia, where Bernstein Liebhard ... Plaintiffs’ Steering Committee. According to an Order ... defendants named in those lawsuits leave to amend ...
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... highlighted a problem which could prove critical to organizations ... system testing, a critical aspect of data security, is ... card industry data security report, every major category out ... scanning and penetration testing. “With all the craziness that ...
(Date:3/28/2015)... 2015 How best to treat and ... in orthopaedic medicine. While diagnostic hip injections are commonly ... pain etiology, research presented today at the American Orthopaedic ... suggests that pain relief from this diagnostic injection may ... , “Our study looked to assess if the amount ...
(Date:3/28/2015)... March 28, 2015 Andrew Hawley of Vintage ... Who psychedelic concert posters. The Who and the Doors played ... August 2, 1968. According to Hawley, “The Who toured the ... halls and college campuses. Perhaps the most famous Who poster ... Morrison and the Doors on August 2, 1968 at the ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2
... Age should not be a factor in determining ... shown that older heart transplant patients do just as ... evaluated all 275 adult patients who received a heart ... and 2000. The patients' mortality and morbidity rates were ...
... and people without liver cancer found that diabetics are stand ... the general population.// ,After taking other factors into account, ... researchers found diabetes nearly tripled the risk of liver cancer. ... for liver cancer, may be boosting the risk even further. ...
... cause skin cancer – melanoma ,however researchers as the number ... number of patients surviving the disease. // Two new studies ... kinds of cancer. In a study conducted by researchers on ... it was discovered that melanoma patients with higher levels of ...
... The most deadly form of skin cancer , advanced ... with tumor proteins, say researchers according to a recent ... with tumor antigens (called MAGE-3) might have on patients’ ... was found that injecting patients with the tumor antigens ...
... a recent study researchers focused on the use ... their impact on cholesterol and C-reactive protein levels. ... the liver that predicts inflammation in the arteries. ... important key to determining cardiovascular risk.,Researchers focused on ...
... the heart's own can, such as raising the heart rate ... a hill but researchers say a pacemaker created by // ... have shown that genetically engineered heart cells from human embryonic ... according to a new study. Researchers injected clusters of human ...
Cached Medicine News:
(Date:3/27/2015)... Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending ... as the country,s manufacturing leader in innovation and economic ... to the  analysis , the industry had the highest ... accounting for 27 percent of average annual R&D spending ... on Medicare Part D - Medicare Part D ...
(Date:3/27/2015)... 2015 The Temple Health & Bioscience District (THBD) ... building at 1802 South First St. in the Temple Medical ... City of Temple to receive funding ... Central Texas Veterans Health Care System, the new facility will ... stage biotechnology and life science companies. ...
(Date:3/27/2015)... A new report from Kalorama Information says that other countries ... Chile , Colombia and ... The healthcare research firm said that while Brazil ... American continent with a population of over 200 million people ... country,s regional economic clout does not necessarily ensure its status ...
Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
... May 2, 2012 Zogenix, Inc. (NASDAQ: ... for the treatment of central nervous system disorders and ... New Drug Application (NDA) to the U.S. Food and ... Zogenix,s lead investigational product candidate for the treatment of ...
... 2012 Oxford BioTherapeutics (OBT) today announces ... Officer (COO) of the OBT group. In this position ... operations based in Basel, Switzerland.  The establishment of a ... global expansion as it progresses its most advanced therapeutic ...
Cached Medicine Technology:Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 2Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 3Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 4Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 5Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 6Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland 2Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland 3
... Plus Retics is a 5-part differential control ... the Abbott CELL-DYN 3200, 3500, 3700 and ... contains nucleated red blood cells that can ... 4000. The assay contains automated and manual ...
... Sickle-Chex is a positive and negative whole ... of Hemoglobin S in solubility tests and ... SICKLEDEX and other manufacturers' solubility kits. ... squeeze dropper vial. The vial dispenses an ...
... blood hematology control manufactured specifically for the ... the Coulter AcT5diff instruments. The composition of ... differential, positioning the populations within the limitations ... product offers 105-day closed-vial stability and 14-day ...
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Medicine Products: